Fig. 6.

GO-203 induces complete regressions of U266 tumors. BALB/c nu/nu mice were injected subcutaneously in the flank with 10⁷ U266 cells. The mice were pair-matched when the tumors were ∼100 mm³. Treatment groups consisted of 10 mice injected intraperitoneally with PBS (vehicle control; ■), 30 mg/kg GO-203 (●), or 30 mg/kg CP-2 (▲) each day for 21 days. Another group was treated with 30 mg/kg GO-203 administered each day for 5 days per week for 3 weeks (♦). Mice were weighed twice weekly, and tumor measurements were performed every 2 days. There was no weight loss in any of the groups. The results are expressed as the mean tumor volume with a S.E. of <15% (A). There was no evidence for recurrence in the two GO-203 treatment groups at 180 days. U266 tumors and tumor implantation sites harvested on day 28 were stained with H&E (B).